Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a sell rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. Lake Street Capital assumed coverage on shares of Verrica Pharmaceuticals in a report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, October 13th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $12.67.

Verrica Pharmaceuticals Stock Performance

Shares of NASDAQ VRCA opened at $3.59 on Friday. The stock’s 50-day moving average is $4.20 and its 200 day moving average is $5.49. The stock has a market cap of $61.68 million, a price-to-earnings ratio of -2.15 and a beta of 1.69. Verrica Pharmaceuticals has a 1-year low of $3.08 and a 1-year high of $9.82. The company has a current ratio of 1.45, a quick ratio of 1.33 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 22.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,360 shares of the company’s stock after purchasing an additional 5,960 shares during the period. Renaissance Technologies LLC owned about 0.19% of Verrica Pharmaceuticals worth $171,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.